Shenzhen Salubris Pharmaceuticals Co., Ltd.

Overview

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company dedicated to the research, development, manufacturing, and distribution of innovative medical solutions. The company focuses on enhancing the quality of life by providing advanced therapeutic options for a variety of health conditions.

Therapeutic areas

API / Drug Master Files

Shenzhen Salubris Pharmaceuticals Co., Ltd. holds 12 active (12 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• TICAGRELOR NON-STERILE BULK DRUG SUBSTANCEActive2026-02-10
• HUMAN UMBILICAL CORD MESENCHYMAL STEM CELL-DERIVED EXOSOMESActive2025-08-15
• MEROPENEM INTERMEDIATEActive2025-04-15
• MEROPENEM AND SODIUM CARBONATE (STERILE BULK)Active2025-03-18
• OSELTAMIVIR PHOSPHATEActive2024-10-08
• EFINACONAZOLEActive2024-05-20
• MEROPENEM (NON-STERILE DRUG SUBSTANCE INTERMEDIATE)Active2023-03-04
• CRUDE MEROPENEMActive2020-11-05
• ENOXAPARIN SODIUM USPActive2018-07-02
• BIVALIRUDINActive2016-03-09
• ENOXAPARIN SODIUM USPActive2013-04-17
• MEROPENEM STERILEActive2010-02-11

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Shenzhen Salubris Pharmaceuticals Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.